The window has closed. On May 28, the third and final petition for review of the Trump administration's Schedule III cannabis rescheduling order was filed with the U.S. Court of Appeals for the District of Columbia Circuit - the last day of a 30-day filing period that opened when the order appeared in the Federal Register. The D.C. Circuit has since consolidated all three petitions into a single case, setting the stage for what promises to be a complex, multi-front legal challenge to one of the most consequential federal cannabis policy shifts in decades.
Who Filed - and What Their Grievances Actually Are
The May 28 petition was brought by a coalition of five parties: New Directions Addiction Recovery Services, a substance abuse clinic in McHenry County, Illinois; Colorado-based psychiatrist Elizabeth "Libby" Stuyt, M.D.; Arizona pain medicine physician Kenneth Finn, M.D.; Cannabis Industry Victims Educating Litigators (CIVEL), an advocacy organization focused on cannabis-related injuries; and MMJ International Holdings, a private pharmaceutical cannabinoid development company whose subsidiary holds an active DEA Schedule I analytical laboratory registration.
That last petitioner is worth a closer look. MMJ's argument isn't philosophical - it's competitive. The company contends that the rescheduling order effectively rewards state-licensed cannabis operators who built their businesses outside the federal Controlled Substances Act framework, while penalizing companies like MMJ that spent years and millions of dollars pursuing the FDA approval pathway, obtaining DEA registration, and building pharmaceutical-grade manufacturing controls. The petition characterizes the order's expedited registration pathway for state licensees as a shortcut around the public-interest standards and diversion-prevention requirements that federally compliant developers had to satisfy. That's a cognizable Article III injury, the petitioners argue - and it's a materially different kind of objection than what the earlier petitioners raised.
Dr. Finn's standing rests on different, though equally specific, ground. He had been designated as a participant in the DEA's now-vacated administrative law judge hearing under former Administrator Anne Milgram, where he argued his pain management practice would be adversely affected by rescheduling. The May 28 petition contends that the Trump DOJ's order requires him to prescribe cannabis products without standardized dosing protocols, package inserts, drug interaction data, or FDA-approved labeling - the informational infrastructure that ordinarily accompanies a Schedule III controlled substance and that physicians rely on to practice responsibly. To put it plainly: Schedule III status without the clinical documentation that Schedule III is supposed to require.
The 13 Legal Arguments That Will Shape the Case
The May 28 petition is notably more detailed than the two that preceded it - from Smart Approaches to Marijuana and the National Drug and Alcohol Screening Association (filed May 4) and from the attorneys general of Nebraska and Indiana (filed May 22, with Louisiana subsequently asking to be dismissed). The latest petition identifies 13 distinct legal issues the coalition plans to develop fully in its opening brief.
Several of those arguments carry significant weight in the current federal legal environment. The petitioners intend to invoke the major questions doctrine - established in West Virginia v. EPA (2022) - arguing that Acting Attorney General Todd Blanche used an ancillary treaty-implementation provision of the CSA to accomplish a rescheduling decision of vast economic and political significance without clear congressional authorization. They also plan to press the Loper Bright Enterprises v. Raimondo (2024) angle, under which courts no longer defer to agency interpretations of ambiguous statutes. If the DOJ's reading of the relevant CSA provision is contested - and the petitioners clearly believe it is - the D.C. Circuit will have to evaluate it de novo.
The coalition further argues that the order creates a constitutionally suspect "hybrid schedule" - a condition-based framework that treats chemically identical cannabis products differently depending on whether they flow through a state medical cannabis program or an FDA-approved pipeline. That's an equal protection argument under the Fifth Amendment's Due Process Clause, and it's one that doesn't have a clean precedent in scheduling law.
The APA notice-and-comment argument will also be significant. The petitioners contend the order bypassed the procedural requirements that typically govern major regulatory actions - a claim that, if accepted, could void the order on procedural grounds alone, without the court needing to reach any of the substantive questions.
What This Means for Licensed Cannabis Operators
Here's the catch for the industry: everything that state-licensed cannabis businesses have been counting on as a consequence of rescheduling - most prominently, relief from the 280E tax deduction disallowance that has suppressed profitability across the board - now sits in genuine legal jeopardy. Schedule III status is what eliminates 280E's application to cannabis businesses. If the D.C. Circuit stays the order pending full briefing and argument, or ultimately vacates it, operators are back to square one on federal tax treatment.
The petitioners have explicitly asked the court to stay the order's effectiveness while litigation proceeds. Whether the D.C. Circuit grants that stay will depend on the standard factors - likelihood of success on the merits, irreparable harm, balance of equities, and public interest - but the sheer number and variety of legal theories on the table suggests the challengers believe they have plausible arguments on multiple fronts.
For multi-state operators (MSOs), vertically integrated cannabis companies, and smaller single-state licensees alike, the operational planning implications are real. Businesses that restructured finances, modeled tax liability, or made wholesale pricing decisions based on anticipated 280E relief would be wise to maintain contingency plans. Same for investors who priced rescheduling into capital allocation decisions. The consolidated case hasn't even reached the briefing stage yet - and these proceedings, once they reach full argument, tend to move on a timeline measured in months, not weeks.
What's striking here is the breadth of the coalition challenging the order. You have a pharmaceutical developer angry about regulatory unfairness, physicians concerned about clinical standards, a substance abuse clinic worried about increased access to cannabis, and a victims' advocacy group focused on cannabis-related psychological harm. These parties don't share a single objection - they share a conclusion. And consolidating their case with SAM and two state attorneys general means the D.C. Circuit will be reading a layered set of arguments from parties with genuinely distinct interests, which can complicate an appellate court's path to a narrow ruling.
The briefing schedule, once set, will determine how quickly the court moves. Until there's a ruling on the stay motion - or, further down the road, on the merits - the rescheduling order remains technically in effect. But licensed operators should treat that status as provisional, not permanent, and plan accordingly.
